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Despite significant improvement over recent decades, oesophageal cancer survival rates remain poor. Neoadjuvant chemoradio-
therapy followed by oesophageal resection is mainstay of therapy for resectable oesophageal tumours. Operative morbidity and
mortality associated with oesophagectomy remain high and complications arise in up to 60% of patients. Management strategies
have moved towards definitive chemoradiotherapy for a number of tumour sites (head and neck, cervical, and rectal) particularly
for squamous pathology. We undertook to perform a review of the current status of morbidity and mortality associated with
oesophagectomy, grading systems determining pathologic response, and data from clinical trials managing patients with definitive
chemoradiotherapy to inform a discussion on the topic.
1. Introduction
Oesophageal cancer is the 8th commonestmalignancyworld-
wide affectingmore than 450,000 people [1, 2]. Overall 5-year
survival is estimated to be between 15 and 25% [1, 3]. While
this appears low, significant improvements in treatment have
been made in recent decades. Prognosis in the 1960s was
considered so dismal that survival beyond two years was con-
sidered long-term and the rates were only 9% [4].
The two main histological subtypes are squamous cell
carcinoma (SCC) and oesophageal adenocarcinoma (OAC),
with rare variants such as spindle cell carcinoma, verrucous
carcinoma, pseudosarcoma, mucoepidermoid carcinoma,
adenosquamous carcinoma, primary oat cell carcinoma, cho-
riocarcinoma, carcinoid tumour, leiomyosarcoma,malignant
melanoma, rhabdomyosarcoma, and lymphomamaking up 1-
2% [5]. Whilst SCC is the most dominant type of esophageal
cancer, the predominant histological subtype is highly vari-
able depending on geographical location. Trends over time
suggest that the overall incidence of SCC is stable or declining
in westernized regions while, in contrast, OAC has overtaken
SCC in most western countries with the incidence having
increased >650% in the USA over the past 35 years [6].
SCC begins in squamous cells and is mainly found in
the upper two thirds of the esophagus. Adenocarcinomas are
derived from gland cells, which make up the mucus lining
in the epithelium, typically in the lower third of the oesoph-
agus. There are three grades of adenocarcinoma based on
Siewert Classification [7]. Type 1 is adenocarcinoma of distal
esophagus and type 2 is a true carcinoma of the cardia, with
type 3 being subcardial gastric cancer infiltrating the distal
oesophagus. Barrett’s oesophagus (BO) is classified by spe-
cialized intestinal metaplasia of the lower oesophagus known
to arise as a result of chronic gastroesophageal reflux disease
(GORD) and ultimately the development of oesophagitis [8].
The condition is associated with an increased risk of cancer
development and patients with oesophagitis have a relative
risk of 4.5 for the development of cancer; this increases to 29.8
in those who have progressed to BO [9].Many additional risk
factors for oesophageal cancer exist including age, gender,
race, obesity, reflux symptoms, smoking, and diet; however
dysplasia remains the sole reliable indicator of adenocarci-
noma development [10].
Oesophagectomy alone orwith neoadjuvant chemoradio-
therapy is themainstay of therapy for nonmetastatic oesopha-
geal cancer [11]. A randomized trial comparing chemotherapy
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followed by surgery with surgery alone in squamous cell car-
cinoma of the oesophagus found that medial overall survival
time was 16 months in the chemosurgery group compared
with 12 months in the surgery alone cohort [12]. Results of
the MAGIC trial whereby patients were randomised to
receive surgery alone or perioperative and postoperative
chemotherapy with Epirubicin, Cisplatin, and Fluorouracil
(ECF) demonstrated 36% 5-year survival for those in the
chemotherapy group and 23% for those in the surgery only
group [13]. The CROSS trial demonstrated a 49.4-month
median overall survival in the chemoradiotherapy-surgery
group compared to 24 months in the surgery alone cohort
[14]. Approximately 25–30% of patients experience complete
pathologic response following neoadjuvant chemoradiother-
apy [14–16].
Even though the trimodal approach has led to prolonged
survival outcomes, the risk of operative complications must
be borne in mind [17]. A number of authors have therefore
asked should every patient undergo oesophagectomy and
how might the patients best suited to chemoradiotherapy
alone be selected? We undertook to perform a review of the
current grading systems pertaining to pathological response,
the current levels of outcome data reporting pathologic resp-
onse rates, and updated operative complication rates in order
to inform a discussion on the topic.
2. Methodology
Relevant medical literature was identified from searches of
PubMed and references cited in appropriate articles iden-
tified. Search terms included oesophageal adenocarcinoma,
squamous cell carcinoma, complete pathological response,
tumour regression grade, clinical trial oesophageal cancer,
multimodal therapy oesophageal cancer, oesophagectomy
morbidity, oesophagectomy mortality, and definitive chemo-
radiotherapy oesophageal cancer. Selection of articles was
based on peer review, journal, and relevance.Where possible,
articles from high-impact peer review journals were cited.
3. Current Tumour Regression
Grading Systems
Attainment of complete pathological response is accepted as a
surrogate marker of survival advantage; however no measure
of histomorphological regression is included in the current
staging nomenclature [18]. One reason is a lack of standard-
isation of tumour regression grading systems; a total of nine
currently exist, 5 exclusively focusing on response at the
primary site and 3 incorporating both nodal and primary
site response (Table 1) [18–26]. The most frequently utilised
regression grading system to date is that of Mandard et al.
[22]. On the basis of gross examination, histology and oeso-
phageal wall involvement primary tumour regression was
classified into five histologic tumour regression grades with
grade one demonstrating complete regression and an absence
of histologically identifiable cancer and fibrosis extending
through the different layers of the oesophageal wall and grade
5 with an absence of regressive changes [22]. The group
estimated survival curves based on typical pathological fea-
tures were associated with survival in addition to tumour
regression grade and determined that after multivariate
analysis regression grades 1–3 and 4-5 remained significant
predictors of disease free survival, highlighting the impor-
tance of tumour regression in the survival of patients with
oesophageal cancer undergoing preoperative chemoradio-
therapy, suggesting that this should be taken into account
when evaluating therapeutic results [22].
More recently, Donohoe et al. applied a comparative
analysis of the existing tumour regression grading systems to
a new 3-point tumour regression grade score using data from
393 consecutive patients undergoing multimodal therapy,
demonstrating that only their novel score and not preexist-
ing scores predicted survival [18]. The same authors argue
that the difficulty with preexisting scoring systems is inter-
pretation if the intermediate scores, for example, Mandard
grades 2–4, whereby scoring presents difficulty with respect
to interpretation of these intermediate grades with respect
to interobserver differences [18]. Authors concluded that no
existing published measure of tumour regression indepen-
dently predicted outcome, compared with the novel 3-point
score they devised. Despite the disparity between grading
scores and the undoubted benefit obtainable from a consen-
sus scoring system, any such score will not allow discrimi-
nation between those patients likely to derive benefit from
nonoperative management.
Since publication of that paper, Lin et al. examined a path-
ologic complete response (pCR) nomogram score to predict
the survival outcomes of patients receiving definitive chemo-
radiotherapy for oesophageal cancer [27]. Patients undergo-
ing analysis (𝑛 = 333) had received chemoradiation without
surgery for oesophageal cancer and amultivariate cox regres-
sion analysis was employed to test potential associations
between clinical outcomes and patient or treatment factors
[27]. A nomogram based on gender, endoscopic ultrasound
findings, standard uptake value (SUV) after therapy, oesoph-
agogastric duodenoscopy (OGD) post-neoadjuvant therapy,
and histological tumour grade was devised. Interestingly,
patients with a nomogram score falling below the median
(<125) had significantlyworse outcomes comparedwith those
with scores above the median (>125). Furthermore, mul-
tivariate cox regression analysis indicated that nomogram
score independently predicted each survival outcome, along
with other patient and disease factors [27]. The group argues
that although further validation of the nomogram score is
required, it may prove useful for stratification of patients at
highest risk of relapse and therefore requiring oesophageal
resection.
Whilst a consensus tumour regression grading system is
undoubtedly advantageous, it is not possible to apply that to
the avoidance of surgery in those patients in whom a com-
plete pathological response is obtained due to the fact that all
of the existing grading systems utilise specimens resected at
the time of surgery. A number of methods of predicting pCR
have been explored, however. Skinner et al. have presented
a validated miRNA signature to predict pCR to neoadjuvant
chemoradiotherapy in oesophageal adenocarcinoma [28].
Three patient cohorts were examined: discovery (𝑛 = 10),
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Table 1: Tumour response grading systems.
Author Complete response Incomplete response No response
Tumor response grading systems that incorporate nodal response and primary site
Meredith et al.
[23]
Complete response: absence of
histological evidence of neoplasia,
gross tumor, or individual cells in the
resected esophageal specimen by light
microscopy but not
immunohistochemical stains
Partial response: change in T or N
stage from preoperative EUS or greater
than 50% reduction in size of tumor
compared pre- and postoperatively
No response: no change in tumor
stage compared to preoperative





absence of any viable tumor
Near-complete: microscopic focus of
viable tumor cells in an otherwise
necrotic specimen with no tumor
remaining in resected lymph nodes
No response: macroscopic
residual viable tumor at primary
site and/or positive lymph nodes
Kim et al. [24] No residual tumor
Residual tumor <1 cm in greatest
dimension and limited to mucosa or
submucosa with no nodal involvement
or primary and microscopic neoplastic
cells in a single regional node
No response: all other tumors
Tumor response grading systems of response at primary site only
Schneider et al.
[25]
0 vital residual tumor cells at primary
site
<10% vital residual tumor cells at
primary site
10%–50% vital residual tumor cells at
primary site




Complete response: no residual cancer
cells
Partial response: 1%–50% residual
tumor
No response: more than 50% of
tumor remains
Mandard et al.
[22] Grade 1: complete regression
Grade 2: isolated cell nests
Grade 3: more residual cancer cells but
fibrosis still predominates
Grade 4: residual cancer




Major response: <10% residual viable
tumor cells >10% residual viable tumor cells
Donington
et al. [26]
No vital residual tumor cells at
primary site
Any residual tumor cells at
primary site
model (𝑛 = 43), and validation (𝑛 = 65). In the discovery
cohort 754 miRNA targets were examined in pretreatment
tumour biopsies and of these 44 of the most significantly
altered selected. The 4 miRNAs significantly predicting pCR
in both the discovery and model group were further assessed
in the validation cohort and these 4 miRNAs were used to
generate an expression profile (MEP) score [28].When comb-
ined with clinical variables, the MEP score provided a vali-
dated means of predicting pCR to neoadjuvant chemoradio-
therapy [28].
A recent study by Wen et al. has examined whether
mRNA markers are useful for the prediction of CRT in
oesophageal squamous cell carcinoma [29]. Gene expression
analysis was carried out on pretreatment biopsies from 28
patients who received neoadjuvant CRT and surgery. Authors
derived a predictionmodel based on the qPCR values of three
genes which was found to have a predictive accuracy of 86%
after leave-out-one cross-validation. This model was then
validated in another cohort of 32 patients with a predictive
accuracy of 81%.Whilst larger validation studies are required,
this may facilitate individualised therapy for oesophageal
squamous cell carcinoma patients and allow discrimina-
tion between those likely to experience complete response
compared to those who would benefit from oesophageal
resection.
Biomarkers in peripheral blood are of interest as the
predictors of response because blood collection is minimally
invasive. Hsu et al. have recently reported identification of
a serum biomarker FAM84B whereby reduced expression
following neoadjuvant chemoradiotherapy was found to be
significantly predictive of pCR [30]. The sample size for this
study is small and the results require further validation in
an independent cohort; nonetheless it represents a promising
advance in the identification of more reliable predictors of
complete pathological response in oesophageal squamous cell
carcinoma capable of delineating those patients best suited to
nonoperative management.
ALDH-1 has been recently identified as a universal
marker of cancer stem cells and progenitor cells thought to
result in tumour regeneration as a result of the somewhat dor-
mant presence of a small population of dysregulated stem
cells following chemoradiotherapy with the capability to
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revive and generate tumours capable of recapitulating the het-
erogeneity of the parent tumour [31, 32]. This concept was
studied by Ajani et al. with regard to tumour regression
who hypothesized that the presence of ALDH-1 could be
associated with pathological response [33]. A cohort of 167
patients, 96% of whom had adenocarcinoma, were divided
into those who had a pCR and those with extremely resistant
cancer. For patients at extremes of this spectrum there was
a significant association between pCR and low ALDH-1
levels analysed by immunohistochemistry with the inverse
association demonstrated for patients with high ALDH-1
levels [33]. While this observation is undoubtedly useful,
it falls short of being capable of predicting pCR in the
entire cohort of patients with ambiguity regarding those with
intermediate ALDH-1 expression levels. Furthermore, due to
the small number of patients with squamous cell pathology,
it is of uncertain benefit in this group.
Smit et al. have examined the samehypothesis in amurine
model in vivo, examining xenograft tumours generated in
NOD/SCID mice from a squamous cell carcinoma (OE21)
and adenocarcinoma (OE33) cell line. CD44+/CD21− sub-
populationswere found to exert higher proliferation rates and
more radioresistance in vitro compared with CD44+/CD24+
cells. Furthermore CD44+/CD24− cells formed xenograft
tumours faster. This was partially validated in human tissue
with the phenotype successfully identified in 50% of poor
responders and none of the complete responders to neoad-
juvant chemoradiotherapy.
As such, a predictive marker of complete pathological
response in this setting remains elusive and will be a require-
ment for delineation of those patients for whom surgery
represents additional unnecessary risk without additional
survival benefit.
Certain pathological exceptions are likely to require indi-
vidual attention. Signet ring morphology has consistently
been associatedwith an unfavourable prognosis and response
to neoadjuvant therapy is rare [34]. Patel et al. studied a
group of 85 patients with signet ring cell adenocarcinoma
compared with a 638-patient reference group and discovered
a lower rate of complete pathological response (9 versus 26%,
𝑃 < 0.001) and more frequent positive margins (24 versus
10%, 𝑃 < 0.001) in the signet ring group [35]. Furthermore,
survival duration was significantly decreased in the signet
ring cohort and patients with signet ring histology whose
resected specimens demonstrated significant downstaging
after neoadjuvant therapy did not differ from the survival
duration of those patients who did not exhibit downstaging
unlike the reference groupwhose survival was improved [35].
4. Current Rates of Operative
Morbidity and Mortality
Oesophageal cancer resection is associated with extremely
high perioperative morbidity and mortality [36]. Neoadju-
vant chemoradiation not only is now the gold standard ther-
apy but has not been shown to increase postoperative mor-
bidity or mortality [37, 38]. Furthermore, there appears to
be no difference in the early or long-term survival between
transthoracic and transhiatal oesophagectomy [39]. Factors
known to increase operative risk include locally advanced
disease, diabetes, dyspnoea, peripheral vascular disease and
previous cerebrovascular accident, international normalised
ratio, and wound contamination at the time of surgery [40].
While recent advances have beenmade with the introduction
of standardised anaesthesia and surgical clinical pathways,
lowering the incidence of complications remains a significant
challenge [36, 41]. Adverse events are decreasing in relation
to the treatment of many medical conditions; however their
incidence with respect to surgery continues to increase [42].
Recognising a lack of standardisation of reporting strate-
gies and definitions, a system for the definition and recording
of complications and quality measures after oesophageal res-
ection has been recently published, dividing complications
into pulmonary, cardiac, gastrointestinal, urologic, throm-
boembolic, neurologic, infectious, and wound related catego-
ries; this has not yet been applied to the reporting of inci-
dence; therefore data preceeding its publication is unreli-
able [41]. The introduction of minimally invasive operative
approaches has again changed the operative paradigm and
while they have been shown to lowermorbidity andmortality,
minor complications are still reported in 50–60% of patients
[43–45]. Minimally invasive oesophagectomy is associated
with a lower incidence of pulmonary complications and shor-
ter hospital stay compared with the open approach [46]. One
recently published series of robotic oesophagectomy reported
rates of recurrent laryngeal nerve palsy in 26.3%, anastomotic
leakage in 14.9%, and pulmonary complications in 9.6% [47].
Ninety-day mortality was 2.5% [47].
Anastomotic leak is a severe and life-limiting conse-
quence of oesophagectomy occurring in 3–30% of patients
and carrying a mortality rate of approximately 18.2% [14,
43, 48–50]. Reported rates are higher in those undergoing
cervical anastomosis compared with thoracic such that rou-
tine radiological assessment of anastomotic integrity has
been suggested for that patient cohort [51]. Presentation of
intrathoracic oesophageal leaks ranges from patients who are
asymptomatic to those with circulatory collapse andmultior-
gan failure [52]. Management is determined based on the size
of the leak, extent of the abscess, and status of the patient with
options including the “three-tube method” (thoracic closed
drainage tube, gastrointestinal decompression tube, and
enteral nutrition), self-expanding metallic stents, endoscopic
vacuum assisted closure, and operative management [52, 53].
Recurrent laryngeal nerve palsy is reported to occur in
36% of cases, occasionally due to intentional excision as a
result of metastatic node involvement, but does not seem to
alter patient survival [54, 55]. Pulmonary complications are a
frequent cause of morbidity in patients undergoing oesopha-
gectomy and are reported to occur in approximately 35% of
cases with an associated mortality of 6% [56]. Recent audits
suggest hospital mortality rates of 7–9% [44]. Some centres
report perioperative mortality rates as low as 1.1%, however
[45]. The national 30-day readmission rate in the US fol-
lowing oesophagectomy is 12.6% with risk factors associated
with readmission including a history of pulmonary disease,
postoperative wound infections, and length of hospital stay
prior to discharge [17].
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5. Definitive Chemoradiotherapy for
Oesophageal Cancer
Pathologic complete response (pCR) has been shown to
predict decreased local and distant recurrence and improved
survival in oesophageal cancer [20]. Current guidelines stip-
ulate the necessity for operative resection in all patients who
are fit to undergo surgery irrespective of the extent of tumour
regression, leaving definitive chemoradiotherapy dCRT as an
alternative for those patients unsuitable for surgery due to
comorbid disease [57]. In recent years the concept of defini-
tive chemoradiotherapy has emerged as a primary treatment
option for a number of squamous cell carcinomas in sites such
as cervix and head and neckwhere salvage surgery is reserved
for those with disease relapse [58, 59]. Furthermore, there
have been several recent reports on a nonoperative approach
for lower rectal cancers [60].
A number of studies to date have reported long term
survival outcome following definitive chemoradiotherapy for
patients with resectable squamous cell carcinoma of the
oesophagus. A definitive answer as to whether this approach
offers similar cure rates with decreased morbidity and mor-
tality has not yet been obtained. Teoh et al. randomized 81
patients with resectablemid- or lower oesophageal squamous
cell carcinoma to receive oesophagectomy or dCRT [61].
Although the overall 5-year survival did not reach statistical
significance it did favour the dCRT group (surgery 29.4%,
dCRT 50%, 𝑃 = 0.147) and the 5-year disease-free survival
also showed a trend towards favouring dCRT (𝑃 = 0.068)
[61]. The RTOG 85-01 trial set the definitive standard for
dCRT in 1992 [62]. This phase III prospective, randomized
trial evaluated the efficacy of four courses of fluorouracil
and cisplatin plus 5,000 cGy of radiation therapy compared
with 6,400 cGy of radiation therapy alone in patients with
adenocarcinoma (𝑛 = 15) or squamous cell carcinoma (𝑛 =
106) of the oesophagus andwas stopped after accumulation of
results from 121 patientswhen a significant survival advantage
for those receiving chemoradiotherapy was identified [62].
Median survival for those receiving radiation was 8.9 months
compared with 12.5 months. Long-term follow-up showed
that 5-year survival was 26% for chemoradiotherapy and 0%
for radiotherapy alone. In those receiving chemoradiother-
apy, persistent disease and locoregional relapse were themain
causes of treatment failure [62]. A follow-up trial (INT 0123)
showed that a higher dose of radiotherapy (64.8Gy) was not
superior in terms of survival or disease control compared
with a lower dose (50.4Gy) but was more toxic [63].
In Europe the use of CRT in the neoadjuvant setting
became more widespread after the publication of several
meta-analyses demonstrating a benefit [64–66]. Stahl et al.
performed a trial for locally advanced SCC of the upper/mid
oesophagus, allocating patients to induction chemotherapy
followed by CRT (40Gy) with surgery or induction chemo-
therapy followed by CRT (65Gy) without surgery [67].
Overall survival did not improvewith the addition of surgery;
however patients in the surgery arm did experience improved
local control and a reduction in death secondary to the cancer
[67]. However, this trial was designed to assess equivalence
and not survival advantage [67].
Cisplatin and fluorouracil represent the mainstay of
chemotherapy although other choices have been examined
including FOLFOX versus fluorouracil and cisplatin, cispla-
tin/irinotecan versus carboplatin/paclitaxel, paclitaxel, car-
boplatin, carboplatin, and paclitaxil (CROSS protocol) [14,
68–70]. Survival rates were similar with FOLFOX compared
with cisplatin and fluorouracil; however the side effect profile
was slightly differentwith increased neuropathy and less renal
dysfunction with FOLFOX [68].
Two trials comparing the use of preoperative CRT fol-
lowed by surgery versus dCRT have been conducted with
almost exclusively squamous cell histology.TheGerman trial,
exclusively SCC, used induction chemotherapy (fluorouracil,
leucovorin, etoposide, and cisplatin for 3 cycles) followed
by chemoradiotherapy (40Gy with cisplatin and etoposide)
followed by either surgery or further radiotherapy [67]. In
the French trial 89% of patients had squamous pathology
and received either split-course radiotherapy (30Gy) or stan-
dard radiotherapy (46Gy) with two cycles of cisplatin and
fluorouracil [71]. Only patients experiencing a response after
induction chemotherapy were randomized; half to further
chemoradiation and half to surgery. Both trials were designed
to assess equivalence. Overall survival at two years was simi-
lar in both arms of both trials. Local control rate at two years
was better for surgery in both trials (66.7% for preopera-
tive CRT versus 57% for dCRT in the French trial and 64.3%
for preoperative CRT and 40.7% for dCRT in the German
trial) [67, 71].
SCOPE 1 was a multicentre UK phase II-III trial com-
paring dCRT (50Gy in 25 fractions with four cycles of
cisplatin/capecitabine) with dCRT and the addition of cetux-
imab, an EGFR antagonist [72]. Patients included a total of
65 with adenocarcinoma, 188 with squamous, and 5 with
undifferentiated pathology. Recruitment was stopped with-
out continuation to phase III because the trial met criteria for
futility. Fewer patients were treatment failure free at 24 weeks
in the CRT plus cetuximab arm than in the CRT alone group
and they also had a shorter median survival (22.1 months
versus 25.4 months 𝑃 = 0.035) [72]. Although the findings
with regard to EFGR inhibitor therapy were negative, the
overall survival for dCRT using modern strategies for patient
selection and therapy delivery was better than pervious
published trials of neoadjuvant CRT and surgery [72].
The issue, however, remains unresolved and a study has
been performed to identify the feasibility of performing a ran-
domized controlled trial comparing neoadjuvant CRT and
dCRT in the UK [73]. Authors concluded that the numbers
of incident eligible patients would be too low to enable such a
study [73]. In patients with squamous cell histologies, CRT
alone with careful follow-up and salvage surgery may be a
reasonable approach for those who attain a pCR; however the
paucity of data outrules any reasonable consideration of this
approach in adenocarcinoma [74]. NCCNGuidelines recom-
mend the use of dCRT for T4b tumours in medically fit and
unfit patients and for resectable tumours in medically unfit
patients. In medically fit patients with resectable tumours,
dCRT is only recommended for cervical SCC oesophageal
cancers and for all patients with adenocarcinoma it is only
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recommended for those who decline or cannot withstand
surgery [75].
Belgian guidelines recommend that the use of dCRT be
restricted to clinical trials for those patients with resectable
disease unless diagnosed with cervical SCC oesophageal
cancers [74]. Considering the body of evidence acquired to
date and the known morbidity and mortality associated with
oesophageal resection, it becomes apparent that clinical trials
addressing this issue should be a priority and further infor-
mation is required to select those patients whomight bemore
appropriately managed with dCRT.
6. Future Considerations
Theviability of dCRTwith surgery reserved for those patients
exhibiting a poor response is entirely dependent on an
accuratemethod of determining true pCR, which is currently
lacking. There are some promising mRNA studies; however
as mentioned they require validation. Studies examining the
accuracy of PET-CT in assessing response in oesophageal
adenocarcinoma have revealed no significant association
betweenmaximum standard uptake value (SUV) and tumour
regression grade [76]. Of a one hundred patient cohort
examined, 80% had histological evidence of residual tumour
in the resected specimen and a complete metabolic response
was not associated with a survival benefit [76]. A cohort of
57 patients were examined by Klayton et al., who identified
that while PET imaging was useful in terms of predicting the
likelihood of residual tumour it was not sensitive enough to
outrule the presence of residual disease [77]. These results
are mirrored by those of Myslivecek et al. who found no
statistically significant correlation between the (18)F-FDG
metabolic response after neoadjuvant CRT and the histopa-
thologic response in a cohort of 73 patients [78]. In a small
series of patients undergoing neoadjuvant CRT for squamous
cell carcinoma of the oesophagus, however, Park et al. did
identify a relationship between change in SUV and likelihood
of a complete response indicating that it may be more useful
in this setting [79]. PET-CT is insufficient alone to determine
a complete clinical response. Cheedella et al. examined 284
patients with oesophageal cancer and found that while 77%
achieved a postneoadjuvant therapy biopsy negative, PET
negative status, and therefore a complete clinical response,
only 31% of patients in fact achieved a pCR following res-
ection [80]. A recently published study by Kukar et al. exami-
ning the role of PET-CT characteristics in oesophageal
adenocarcinoma patients has demonstrated that a change in
SUV value less than 45% is associated with patients with
residual disease but not complete pathological response [81].
No altered recommendationwith respect to surgical resection
is possible based on PET SUV in the primary tumour [81].
The possibility that SUV is a suboptimal parameter for
classification has been explored. A group of 45 patients exam-
ined by Metser et al. evaluated tumours based on PET
response criteria in solid tumour, based on criteria including
SUL (standardized uptake value normalised to lean body
mass), SUL tumour/liver ratio, and % change in SUL. Results
demonstrated a positive correlation between posttherapy
SUL ratio, % change in SUL, and % change in SUL ratio with
clinical response (𝑃 = 0.025, 0.035, and 0.03, resp.); however
further validation of this is required [82].
7. Conclusion
Despite surgical advances and more minimally invasive
approaches, morbidity and mortality associated with oeso-
phagectomy remain high. Definitive CRT has been used for
patients unfit to undergo operative resection for many years
and response rates have improved with the development
of contemporary therapeutic regimens. With movement to
more targeted systemic treatments it is likely that rates of pCR
will increase. Accurate assessment of tumour response and
regression without the information attained at pathological
assessment postresection remains a significant challenge.
Current modalities, endoscopy and PET-CT, are not suffi-
ciently sensitive to allow reliable determination of complete
response. In the future, research to identify those patients
whomay not benefit fromoesophagectomy is warranted, par-
ticularly the identification of circulating biomarkers which
predict disease response.
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